Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis’ Exelon recommended for expanded use
The recommendation will be taken into account by the FDA when deciding whether or not to approve the expanded indication for the drug, which is already approved for
The recommendation will be taken into account by the FDA when deciding whether or not to approve the expanded indication for the drug, which is already approved for
Because blood-clotting proteins are large, relatively unstable molecules, current hemophilia therapies can only be administered intravenously, which is an invasive and technically demanding procedure. It is presently not
As part of the International Clinical Trials Registry Platform, a major initiative aimed at standardizing the way information on medical studies is made available to the public through
In April, BioLineRx began phase I clinical trials to evaluate the safety and determine the pharmacokinetic profile of the compound, BL-1020, in humans. “We continue to be very
The trial, which will enroll 3400 patients with a history of recent heart attack, will focus on African-American heart patients who carry an at-risk variant of one of
Azilect was approved in Europe and Israel in 2005, where it has been successfully launched. In the EU, it is now marketed in 13 countries in collaboration with
The dose-escalating phase I study will determine if Seneca valley virus (SVV-001) can be systemically administered safely to patients with certain types of advanced neuroendocrine cancers, including small
The novel oral formulation provides rapid absorption of apomorphine directly into the bloodstream after sublingual (under the tongue) administration. This novel formulation would offer patients an improved alternative
The study, expected to enroll approximately 50 patients, will evaluate the safety, tolerability and pharmacokinetics of escalating single and multiple doses of VX-770 in healthy volunteers, and also
According to Pfizer, the approval makes Aromasin the first and only aromatase inhibitor approved in Canada for the indication. Results from the study that supported this approval showed